王者荣耀比赛排名新版

Incyte Corp traded at $72.20 this Friday September 9th, increasing $0.48 or 0.67 percent since the previous trading session. Looking back, over the last four weeks, Incyte Corp gained 2.60 percent. Over the last 12 months, its price rose by 1.52 percent. Looking ahead, we forecast Incyte Corp to be priced at 68.19 by the end of this quarter and at 62.46 in one year, according to 王者荣耀电竞(江西)积分排榜 global macro models projections and analysts expectations.

Stock Price
72.20
Daily Change
0.67%
Yearly
1.52%

Ok
王者荣耀电竞(江西)积分排榜 members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The 王者荣耀电竞(江西)积分排榜 Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 17.38 -0.04 -0.23% 8.02%
Agenus 2.69 0.07 2.67% -58.62%
Agios Pharmaceuticals 34.14 0.14 0.41% -24.44%
Alnylam Pharmaceuticals 223.27 -3.03 -1.34% 17.79%
Amgen 247.69 2.24 0.91% 15.88%
BioCryst Pharmaceuticals 13.45 -0.28 -2.04% -11.51%
Biogen 211.84 3.86 1.86% -29.34%
Bluebird Bio 7.14 0.03 0.42% -60.07%
BioMarin Pharmaceutical 92.93 -0.08 -0.09% 19.17%
Bristol-Myers Squibb 70.16 0.78 1.12% 11.14%
ChemoCentryx 51.49 -0.11 -0.21% 233.92%
Clovis Oncology 1.15 0.05 4.55% -73.62%
CTI Biopharma 6.34 -0.04 -0.63% 99.37%
Exelixis 17.90 0.09 0.51% -10.32%
Gilead Sciences 65.28 0.18 0.28% -8.04%
Intercept Pharmaceuticals 17.00 -0.13 -0.76% 16.04%
Idera Pharmaceuticals 0.52 0.03 5.25% -51.81%
Incyte Corp 72.20 0.48 0.67% 1.52%
Ionis Pharmaceuticals 46.84 2.57 5.81% 29.79%
Eli Lilly 317.70 2.20 0.70% 32.65%
MacroGenics 4.24 -0.01 -0.24% -83.11%
Merck & Co 87.34 -0.08 -0.09% 18.91%
Moderna Inc 142.28 1.00 0.71% -68.34%
Mirati Therapeutics 84.77 0.42 0.50% -48.81%
Neurocrine Biosciences 106.51 -0.17 -0.16% 10.10%
Nektar Therapeutics 3.74 -0.02 -0.53% -76.55%
Lumos Pharma Inc. 8.74 0.14 1.63% -21.89%
Novartis 79.36 0.58 0.74% 0.88%
Novartis 82.60 1.34 1.65% -3.31%
Puma Biotechnology 2.74 0.18 7.03% -61.62%
Pfizer 47.84 0.76 1.61% 4.94%
PTC Therapeutics 53.64 -0.21 -0.39% 28.33%
Ultragenyx Pharmaceutical 49.24 1.51 3.16% -51.58%
Regeneron Pharmaceuticals 724.32 15.47 2.18% 11.35%
Seattle Genetics 155.47 2.83 1.85% 2.61%
Sarepta Therapeutics 118.44 -0.80 -0.67% 47.19%
Vertex Pharmaceuticals 292.11 3.12 1.08% 54.91%

Indexes Price Day Year
USND 12112 250.18 2.11% -19.87%
US500 4067 61.18 1.53% -8.77%
USNDX 12588 267.10 2.17% -18.47%

Incyte Corp
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.